drugset
Drugs / SENTI-202
last change Feb 2026 re-read 3 minutes ago

SENTI-202

Cell therapy

Developed for
acute myeloid leukemia
Investigated by
Senti Biosciences

Trials 1

today NCT06325748 · Ph 1
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06325748 Apr 2024 → Feb 2026 overdue acute myeloid leukemia Senti Biosciences Active not recruiting No outcome recorded

Press releases naming this drug 10 releases

DateIssuerRelease
2025-12-08 Senti Biosciences Promising results from an ongoing Phase I multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) sentibio.com ↗
2025-12-08 Senti Biosciences Correlative data from an ongoing Phase 1, multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action sentibio.com ↗
2025-04-30 Senti Biosciences SENTI-202 CD33 OR FLT3 NOT EMCN Logic-Gated Gene Circuit Components Selectively Target AML while Protecting Human HSC/HPCs from Off-Tumor Toxicity in a Humanized Mouse Model sentibio.com ↗
2025-04-29 Senti Biosciences First-In-Human, Multicenter Study of SENTI-202, a CD33/FLT3 Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Hematologic Malignancies including AML: Correlative Data sentibio.com ↗
2025-04-27 Senti Biosciences First-In-Human, Multicenter Study of SENTI-202, a CD33/FLT3 Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Hematologic Malignancies including AML: Clinical Data sentibio.com ↗
2024-04-08 Senti Biosciences Preclinical data supporting the Phase 1 trial design of SENTI-202, a next generation allogeneic logic-gated selective CAR-NK cell therapy, engineered to overcome key limitations of first generation cell therapies in AML sentibio.com ↗
2023-12-11 Senti Biosciences Calibrated Release IL15-Expressing Bivalent CD33 and/or FLT3 Logic Gated Gene Circuit CAR-NK Cell Therapy (from SENTI-202 gene circuit) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models sentibio.com ↗
2023-04-17 Senti Biosciences Preclinical development of SENTI-202, an off-the-shelf Logic Gated CAR-NK cell therapy, for the treatment of CD33/FLT3+ hematologic malignancies including AML sentibio.com ↗
2022-12-10 Senti Biosciences SENTI-202, a Selective, Off-the-Shelf, Preclinical CAR-NK Cell Therapy with CD33 and/or FLT3 Activating CAR, Healthy Cell Protection from Endomucin (EMCN) Inhibitory CAR and Calibrated Release IL-15 for Hematologic Malignancies Including AML sentibio.com ↗
2022-05-18 Senti Biosciences Logic Gated FLT3 OR CD33 NOT EMCN CAR-NK Cell Therapy (SENTI-202) for Precise Targeting of AML sentibio.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SENTI-202 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06325748 ↗
Action Deplete “designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies” NCT06325748 ↗
Modality Cell therapy “an off-the-shelf logic gated CAR NK cell therapy” NCT06325748 ↗